The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

H Razavi; I Waked; C Sarrazin; R P Myers; R Idilman; F Calinas; W Vogel; M C Mendes Correa; C Hézode; P Lázaro; U Akarca; S Aleman; I Balık; T Berg; F Bihl; M Bilodeau; A J Blasco; C E Brandão Mello; P Bruggmann; M Buti; J L Calleja; H Cheinquer; P B Christensen; M Clausen; H S M Coelho; M E Cramp; G J Dore; W Doss; A S Duberg; M H El-Sayed; G Ergör; G Esmat; K Falconer; J Félix; M L G Ferraz; P R Ferreira; S Frankova; J García-Samaniego; J Gerstoft; J A Giria; F L Gonçales; E Gower; M Gschwantler; M Guimarães Pessôa; S J Hindman; H Hofer; P Husa; M Kåberg; K D E Kaita; A Kautz; S Kaymakoglu; M Krajden; H Krarup; W Laleman; D Lavanchy; R T Marinho; P Marotta; S Mauss; C Moreno; K Murphy; F Negro; V Nemecek; N Örmeci; A L H Øvrehus; J Parkes; K Pasini; K M Peltekian; A Ramji; N Reis; S K Roberts; W M Rosenberg; F Roudot-Thoraval; S D Ryder; R Sarmento-Castro; D Semela; M Sherman; G E Shiha; W Sievert; J Sperl; P Stärkel; R E Stauber; A J Thompson; P Urbanek; P Van Damme; I van Thiel; H Van Vlierberghe; D Vandijck; H Wedemeyer; N Weis; J Wiegand; A Yosry; A Zekry; M Cornberg; B Müllhaupt; C Estes

doi:10.1111/jvh.12248

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

H Razavi, I Waked, C Sarrazin, R P Myers, R Idilman, F Calinas, W Vogel, M C Mendes Correa, C Hézode, P Lázaro, U Akarca, S Aleman, I Balık, T Berg, F Bihl, M Bilodeau, A J Blasco, C E Brandão Mello, P Bruggmann, M ButiJ L Calleja, H Cheinquer, P B Christensen, M Clausen, H S M Coelho, M E Cramp, G J Dore, W Doss, A S Duberg, M H El-Sayed, G Ergör, G Esmat, K Falconer, J Félix, M L G Ferraz, P R Ferreira, S Frankova, J García-Samaniego, J Gerstoft, J A Giria, F L Gonçales, E Gower, M Gschwantler, M Guimarães Pessôa, S J Hindman, H Hofer, P Husa, M Kåberg, K D E Kaita, A Kautz, S Kaymakoglu, M Krajden, H Krarup, W Laleman, D Lavanchy, R T Marinho, P Marotta, S Mauss, C Moreno, K Murphy, F Negro, V Nemecek, N Örmeci, A L H Øvrehus, J Parkes, K Pasini, K M Peltekian, A Ramji, N Reis, S K Roberts, W M Rosenberg, F Roudot-Thoraval, S D Ryder, R Sarmento-Castro, D Semela, M Sherman, G E Shiha, W Sievert, J Sperl, P Stärkel, R E Stauber, A J Thompson, P Urbanek, P Van Damme, I van Thiel, H Van Vlierberghe, D Vandijck, H Wedemeyer, N Weis, J Wiegand, A Yosry, A Zekry, M Cornberg, B Müllhaupt, C Estes

Research output: Contribution to journal › Journal article › Research › peer-review

346 Citations (Scopus)

Abstract

The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modelling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. In addition, the model was used to estimate the change in the total number of HCV infections, the disease progression and mortality in 2013-2030. Finally, expert panel consensus was used to capture current treatment practices in each country. Using today's treatment paradigm, the total number of HCV infections is projected to decline or remain flat in all countries studied. However, in the same time period, the number of individuals with late-stage liver disease is projected to increase. This study concluded that the current treatment rate and efficacy are not sufficient to manage the disease burden of HCV. Thus, alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver-related deaths from increasing.

Original language	English
Journal	Journal of Viral Hepatitis
Volume	21
Issue number	Suppl 1
Pages (from-to)	34-59
Number of pages	26
ISSN	1352-0504
DOIs	https://doi.org/10.1111/jvh.12248
Publication status	Published - May 2014

Access to Document

10.1111/jvh.12248

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

Razavi, H., Waked, I., Sarrazin, C., Myers, R. P., Idilman, R., Calinas, F., Vogel, W., Mendes Correa, M. C., Hézode, C., Lázaro, P., Akarca, U., Aleman, S., Balık, I., Berg, T., Bihl, F., Bilodeau, M., Blasco, A. J., Brandão Mello, C. E., Bruggmann, P., ... Estes, C. (2014). The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. Journal of Viral Hepatitis, 21(Suppl 1), 34-59. https://doi.org/10.1111/jvh.12248

@article{8bd8b3b36c2f4467942be85c7392ecb8,

title = "The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm",

abstract = "The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modelling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. In addition, the model was used to estimate the change in the total number of HCV infections, the disease progression and mortality in 2013-2030. Finally, expert panel consensus was used to capture current treatment practices in each country. Using today's treatment paradigm, the total number of HCV infections is projected to decline or remain flat in all countries studied. However, in the same time period, the number of individuals with late-stage liver disease is projected to increase. This study concluded that the current treatment rate and efficacy are not sufficient to manage the disease burden of HCV. Thus, alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver-related deaths from increasing.",

author = "H Razavi and I Waked and C Sarrazin and Myers, {R P} and R Idilman and F Calinas and W Vogel and {Mendes Correa}, {M C} and C H{\'e}zode and P L{\'a}zaro and U Akarca and S Aleman and I Balık and T Berg and F Bihl and M Bilodeau and Blasco, {A J} and {Brand{\~a}o Mello}, {C E} and P Bruggmann and M Buti and Calleja, {J L} and H Cheinquer and Christensen, {P B} and M Clausen and Coelho, {H S M} and Cramp, {M E} and Dore, {G J} and W Doss and Duberg, {A S} and El-Sayed, {M H} and G Erg{\"o}r and G Esmat and K Falconer and J F{\'e}lix and Ferraz, {M L G} and Ferreira, {P R} and S Frankova and J Garc{\'i}a-Samaniego and J Gerstoft and Giria, {J A} and Gon{\c c}ales, {F L} and E Gower and M Gschwantler and {Guimar{\~a}es Pess{\^o}a}, M and Hindman, {S J} and H Hofer and P Husa and M K{\aa}berg and Kaita, {K D E} and A Kautz and S Kaymakoglu and M Krajden and H Krarup and W Laleman and D Lavanchy and Marinho, {R T} and P Marotta and S Mauss and C Moreno and K Murphy and F Negro and V Nemecek and N {\"O}rmeci and {\O}vrehus, {A L H} and J Parkes and K Pasini and Peltekian, {K M} and A Ramji and N Reis and Roberts, {S K} and Rosenberg, {W M} and F Roudot-Thoraval and Ryder, {S D} and R Sarmento-Castro and D Semela and M Sherman and Shiha, {G E} and W Sievert and J Sperl and P St{\"a}rkel and Stauber, {R E} and Thompson, {A J} and P Urbanek and {Van Damme}, P and {van Thiel}, I and {Van Vlierberghe}, H and D Vandijck and H Wedemeyer and N Weis and J Wiegand and A Yosry and A Zekry and M Cornberg and B M{\"u}llhaupt and C Estes",

note = "{\textcopyright} 2014 John Wiley & Sons Ltd.",

year = "2014",

month = may,

doi = "10.1111/jvh.12248",

language = "English",

volume = "21",

pages = "34--59",

journal = "Journal of Viral Hepatitis",

issn = "1352-0504",

publisher = "Wiley-Blackwell",

number = "Suppl 1",

}

Razavi, H, Waked, I, Sarrazin, C, Myers, RP, Idilman, R, Calinas, F, Vogel, W, Mendes Correa, MC, Hézode, C, Lázaro, P, Akarca, U, Aleman, S, Balık, I, Berg, T, Bihl, F, Bilodeau, M, Blasco, AJ, Brandão Mello, CE, Bruggmann, P, Buti, M, Calleja, JL, Cheinquer, H, Christensen, PB, Clausen, M, Coelho, HSM, Cramp, ME, Dore, GJ, Doss, W, Duberg, AS, El-Sayed, MH, Ergör, G, Esmat, G, Falconer, K, Félix, J, Ferraz, MLG, Ferreira, PR, Frankova, S, García-Samaniego, J, Gerstoft, J, Giria, JA, Gonçales, FL, Gower, E, Gschwantler, M, Guimarães Pessôa, M, Hindman, SJ, Hofer, H, Husa, P, Kåberg, M, Kaita, KDE, Kautz, A, Kaymakoglu, S, Krajden, M, Krarup, H, Laleman, W, Lavanchy, D, Marinho, RT, Marotta, P, Mauss, S, Moreno, C, Murphy, K, Negro, F, Nemecek, V, Örmeci, N, Øvrehus, ALH, Parkes, J, Pasini, K, Peltekian, KM, Ramji, A, Reis, N, Roberts, SK, Rosenberg, WM, Roudot-Thoraval, F, Ryder, SD, Sarmento-Castro, R, Semela, D, Sherman, M, Shiha, GE, Sievert, W, Sperl, J, Stärkel, P, Stauber, RE, Thompson, AJ, Urbanek, P, Van Damme, P, van Thiel, I, Van Vlierberghe, H, Vandijck, D, Wedemeyer, H, Weis, N, Wiegand, J, Yosry, A, Zekry, A, Cornberg, M, Müllhaupt, B & Estes, C 2014, 'The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm', Journal of Viral Hepatitis, vol. 21, no. Suppl 1, pp. 34-59. https://doi.org/10.1111/jvh.12248

TY - JOUR

T1 - The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

AU - Razavi, H

AU - Waked, I

AU - Sarrazin, C

AU - Myers, R P

AU - Idilman, R

AU - Calinas, F

AU - Vogel, W

AU - Mendes Correa, M C

AU - Hézode, C

AU - Lázaro, P

AU - Akarca, U

AU - Aleman, S

AU - Balık, I

AU - Berg, T

AU - Bihl, F

AU - Bilodeau, M

AU - Blasco, A J

AU - Brandão Mello, C E

AU - Bruggmann, P

AU - Buti, M

AU - Calleja, J L

AU - Cheinquer, H

AU - Christensen, P B

AU - Clausen, M

AU - Coelho, H S M

AU - Cramp, M E

AU - Dore, G J

AU - Doss, W

AU - Duberg, A S

AU - El-Sayed, M H

AU - Ergör, G

AU - Esmat, G

AU - Falconer, K

AU - Félix, J

AU - Ferraz, M L G

AU - Ferreira, P R

AU - Frankova, S

AU - García-Samaniego, J

AU - Gerstoft, J

AU - Giria, J A

AU - Gonçales, F L

AU - Gower, E

AU - Gschwantler, M

AU - Guimarães Pessôa, M

AU - Hindman, S J

AU - Hofer, H

AU - Husa, P

AU - Kåberg, M

AU - Kaita, K D E

AU - Kautz, A

AU - Kaymakoglu, S

AU - Krajden, M

AU - Krarup, H

AU - Laleman, W

AU - Lavanchy, D

AU - Marinho, R T

AU - Marotta, P

AU - Mauss, S

AU - Moreno, C

AU - Murphy, K

AU - Negro, F

AU - Nemecek, V

AU - Örmeci, N

AU - Øvrehus, A L H

AU - Parkes, J

AU - Pasini, K

AU - Peltekian, K M

AU - Ramji, A

AU - Reis, N

AU - Roberts, S K

AU - Rosenberg, W M

AU - Roudot-Thoraval, F

AU - Ryder, S D

AU - Sarmento-Castro, R

AU - Semela, D

AU - Sherman, M

AU - Shiha, G E

AU - Sievert, W

AU - Sperl, J

AU - Stärkel, P

AU - Stauber, R E

AU - Thompson, A J

AU - Urbanek, P

AU - Van Damme, P

AU - van Thiel, I

AU - Van Vlierberghe, H

AU - Vandijck, D

AU - Wedemeyer, H

AU - Weis, N

AU - Wiegand, J

AU - Yosry, A

AU - Zekry, A

AU - Cornberg, M

AU - Müllhaupt, B

AU - Estes, C

PY - 2014/5

Y1 - 2014/5

N2 - The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modelling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. In addition, the model was used to estimate the change in the total number of HCV infections, the disease progression and mortality in 2013-2030. Finally, expert panel consensus was used to capture current treatment practices in each country. Using today's treatment paradigm, the total number of HCV infections is projected to decline or remain flat in all countries studied. However, in the same time period, the number of individuals with late-stage liver disease is projected to increase. This study concluded that the current treatment rate and efficacy are not sufficient to manage the disease burden of HCV. Thus, alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver-related deaths from increasing.

AB - The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modelling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. In addition, the model was used to estimate the change in the total number of HCV infections, the disease progression and mortality in 2013-2030. Finally, expert panel consensus was used to capture current treatment practices in each country. Using today's treatment paradigm, the total number of HCV infections is projected to decline or remain flat in all countries studied. However, in the same time period, the number of individuals with late-stage liver disease is projected to increase. This study concluded that the current treatment rate and efficacy are not sufficient to manage the disease burden of HCV. Thus, alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver-related deaths from increasing.

U2 - 10.1111/jvh.12248

DO - 10.1111/jvh.12248

M3 - Journal article

C2 - 24713005

SN - 1352-0504

VL - 21

SP - 34

EP - 59

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

IS - Suppl 1

ER -

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

Abstract

Access to Document

AUB Link

Fingerprint

Cite this